Investment Analysts’ Recent Ratings Updates for Climb Bio (CLYM)

Several analysts have recently updated their ratings and price targets for Climb Bio (NASDAQ: CLYM):

• 6/12/2026 – Climb Bio had its “outperform” rating reaffirmed by Wedbush. They now have a $17.00 price target on the stock.
• 6/11/2026 – Climb Bio had its price target raised by BTIG Research from $19.00 to $20.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Climb Bio is now covered by Guggenheim. They set a “buy” rating and a $35.00 price target on the stock.
• 6/8/2026 – Climb Bio is now covered by Guggenheim. They set a “buy” rating and a $35.00 price target on the stock.
• 6/8/2026 – Climb Bio had its “buy” rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.
• 5/12/2026 – Climb Bio had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a “buy” rating on the stock.
• 5/9/2026 – Climb Bio was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Climb Bio had its price target raised by Wedbush from $15.00 to $17.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Climb Bio was given a new $21.00 price target by Robert W. Baird.
• 5/6/2026 – Climb Bio had its price target raised by BTIG Research from $8.00 to $19.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Climb Bio is now covered by Chardan Capital. They set a “buy” rating and a $22.00 price target on the stock.
• 4/21/2026 – Climb Bio had its price target raised by Oppenheimer Holdings, Inc. from $10.00 to $18.00. They now have an “outperform” rating on the stock.
• 4/20/2026 – Climb Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.